Irritable bowel syndrome: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
|||
| (8 intermediate revisions by 3 users not shown) | |||
| Line 2: | Line 2: | ||
#psychosocial factors | #psychosocial factors | ||
#altered gut motility | #altered gut motility | ||
#hypersensitive intestinal pain | #hypersensitive intestinal pain perception | ||
== | ==Evaluation== | ||
===Criteria=== | ===Criteria=== | ||
#Three months of pain: | #Three months of [[abdominal pain]]: | ||
##relieved by defecation | ##relieved by defecation | ||
## | ##associated with change of stool freq | ||
##related to a change in stool consistency | ##related to a change in stool consistency | ||
#AND, 2 or more of the following symptoms 25% of the time | #AND, 2 or more of the following symptoms 25% of the time | ||
## >3 bm per day or < 3 bm per week | ##>3 bm per day or < 3 bm per week | ||
## altered stool form | ##altered stool form | ||
## altered stool passage | ##altered stool passage | ||
## passage of mucous | ##passage of mucous | ||
## bloating | ##bloating | ||
==Workup== | ==Workup== | ||
*Diagnosis of exclusion | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
*[[Post-infectious irritable bowel syndrome]] | *[[Post-infectious irritable bowel syndrome]] | ||
*See [[abdominal pain]] | |||
==Management== | ==Management== | ||
*Consider prescribing [[ondansetron]] up to 24 mg/d for IBS-D<ref>Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63:1617-1625.</ref> | |||
*Typical bowel regimen treatments for IBS-C | |||
**May consider low-dose [[TCA]] if appropriate follow up with PCP will occur | |||
==See Also== | ==See Also== | ||
| Line 32: | Line 37: | ||
[http://digestive.niddk.nih.gov/ddiseases/pubs/ibs/ibs_508.pdf Irritable Bowel Syndrome] (National Digestive Diseases Information Clearinghouse) | [http://digestive.niddk.nih.gov/ddiseases/pubs/ibs/ibs_508.pdf Irritable Bowel Syndrome] (National Digestive Diseases Information Clearinghouse) | ||
== | ==References== | ||
<references/> | |||
[[Category:GI]] | [[Category:GI]] | ||
Latest revision as of 21:47, 29 September 2019
Background
- psychosocial factors
- altered gut motility
- hypersensitive intestinal pain perception
Evaluation
Criteria
- Three months of abdominal pain:
- relieved by defecation
- associated with change of stool freq
- related to a change in stool consistency
- AND, 2 or more of the following symptoms 25% of the time
- >3 bm per day or < 3 bm per week
- altered stool form
- altered stool passage
- passage of mucous
- bloating
Workup
- Diagnosis of exclusion
Differential Diagnosis
Management
- Consider prescribing ondansetron up to 24 mg/d for IBS-D[1]
- Typical bowel regimen treatments for IBS-C
- May consider low-dose TCA if appropriate follow up with PCP will occur
See Also
External Links
Patient Information
Irritable Bowel Syndrome (National Digestive Diseases Information Clearinghouse)
References
- ↑ Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63:1617-1625.